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ABSTRACT Lung cancer is the most lethal cancer type worldwide, with the majority of patients
presenting with advanced stage disease. Targeting early stage disease pathogenesis would allow dramatic
improvements in lung cancer patient survival. Recently, cell migration has been shown to be an integral
process in early lung cancer ontogeny, with preinvasive lung cancer cells shown to migrate across normal
epithelium prior to developing into invasive disease. TP53 mutations are the most abundant mutations in
human nonsmall cell lung cancers and have been shown to increase cell migration via regulation of Rho-
GTPase protein activity. In this review, we explore the possibility of targeting TP53-mediated Rho-GTPase
activity in early lung cancer and the opportunities for translating this preclinical research into effective
therapies for early stage lung cancer patients.
Introduction
Lung cancer is the most lethal cancer type worldwide, with a mortality rate greater than breast, colorectal
and prostate cancer combined [1]. Nonsmall cell lung cancers (NSCLCs) account for ∼85% of disease [2]
and include squamous cell carcinoma (SqCC), adenocarcinoma (ADC) and large cell carcinoma. Although
5-year post-operative survival is 50% for early-stage (stage I/II) NSCLC, >50% of patients present with
stage IV disease that is associated with an abysmal 2% 5-year survival [3]. This is due to our limited
understanding of the pathomechanisms driving lung cancer ontogeny, as well as a lack of effective
biomarkers and screening tools for diagnosing patients with early stage disease. Thus, in order to identify
and treat lung cancers more effectively, an improved understanding of the biochemical, molecular and
cellular changes that accompany early lung cancer development is required.
It has been noted through post mortem studies and in patients undergoing longitudinal bronchoscopic
surveillance that both preinvasive lesions and invasive SqCCs frequently develop at widely dispersed
anatomical locations [4–6]. Indeed, in surveillance studies using autofluorescence bronchoscopy (AFB) and
computed tomography, almost 60% of invasive lung cancers were observed in anatomically distinct sites
from initially detected preinvasive lesions [7]. More recently, we found that preinvasive SqCC lesions
exhibiting TP53 mutations invariably spread throughout the bronchial tree via discontinuous cell
migration prior to disease progression [8]. These observations suggest that epithelial cell migration is an
integral component of NSCLC development. In this review we focus on the role of cell migration as a
potential therapeutic target for early lung cancers.
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TP53 mutation, Rho-GTPase signalling and cancer cell migration
TP53 is the most consistently and frequently mutated gene in all NSCLCs, with mutations observed in
>80% of SqCCs [9] and >45% of ADCs [10]. Functionally, wild-type TP53 proteins play critical roles in
DNA repair, cell cycle regulation, apoptosis and inhibition of cell migration [11]. At a molecular and
cellular level, mutations in TP53 promote increased cancer cell migration by altering the cell’s internal
cytoskeleton via indirect regulation of the Rho-GTPase family of proteins [12].
Rho-GTPase proteins coordinate cellular movement by promoting a “grow, grip, pull” system involving
cytoskeletal growth at the cell’s leading edge, adhesion to the extracellular matrix (ECM) and cytoskeletal
contraction to pull the cell forward [13]. Rho-GTPases cycle between an inactive GDP-bound state to the
active GTP-bound state upon activation by guanine nucleotide exchange factors (GEFs) [14]. The
activation of these GEFs are regulated by upstream phosphoinositide 3-kinase (PI3K) [13]. Thus, PI3K
activity, via signalling from membrane-associated receptor tyrosine kinase proteins, regulates Rho-GTPase
activation and cell migration (figure 1).
Well-studied Rho-GTPase family members involved in this cell migration system include RhoA, Rac1 and
Cdc42, each of which has important roles in the regulation of cell motility. Generally, Cdc42 functions to
regulate cell polarity and the formation of actin microspikes and filopodia formation, while Rac1 mediates
the formation of larger membrane protrusions (lamellipodia) at the leading edge of cell. Finally, RhoA is
involved in focal adhesion formation, actomyosin contraction, stress fibre formation and retraction of the
cell’s tail [15] (figure 2). Additional components of this system include effector proteins such as
Rho-associated kinase (ROCK) that “grow” the actin-based cytoskeleton, integrins that “grip” the ECM
and myosin proteins bound to this actin cytoskeleton that provide contractile “pull” forces. Downstream of
Rho-GTPases, other effector proteins including mDia, WAVE, N-WASP and PAR6 also coordinate Rac1,
RhoA and Cdc42 functions including actin polymerisation, actomyosin contraction and regulation of cell
polarity (figure 3) [16, 17].
In normal, noncancerous cells, activation of TP53 following DNA damage or other cellular stress increases
phosphatase and tensin homologue (PTEN) activity, leading to inhibition of PI3K, inhibition of
downstream GEF activation and reduced Rho-GTPase-dependent cell migration (figure 1). However, in
cells exhibiting mutant TP53 this process is disrupted leading to a lack of PTEN-mediated PI3K inhibition,
ectopic GEF signalling and enhanced cell migration. In particular, elegant studies using fluorescence
lifetime imaging (FLIM)-fluorescence resonance energy transfer (FRET) microscopy in TP53-mutant
pancreatic ductal adenocarcinoma cells demonstrate increased motility and invasion in three-dimensional
assays in vitro and in vivo [18]. Similarly, fibroblasts derived from TP53-deletion mice showed marked
upregulation of GTP-bound RhoA activity and an increased capacity to migrate and invade in comparison
with their wild-type counterparts [19]. In addition, human melanocytes with mutated TP53 demonstrated
an almost five-fold increase in GTP-bound RhoA activity, coupled with increased migratory capacity [19].
Furthermore, TP53 was found to regulate Cdc42-mediated filopodia formation and cell polarisation in
mouse embryonic fibroblasts (MEFs), and TP53-deficient MEFs exhibited constitutive filopodia and an
increased ability to migrate [20]. Thus, a clear regulatory interplay exists between TP53 mutations and
increased Rho-GTPase activity, contributing to enhanced cancer cell migration.
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FIGURE 1 Receptor tyrosine kinase (RTK) responds to external stimuli including extracellular matrix components
and chemokines and subsequently activates phosphoinositide 3-kinase (PI3K) to produce phosphatidylinositol
(3,4,5)-trisphosphate (PIP3). This, in turn, activates Rho-guanine nucleotide exchange factors (GEF), mediating
Rho-GTPase activation and cell migration. Wild-type p53, via phosphatase and tensin homologue (PTEN),
negatively regulates PI3K activity and Rho-GTPase-mediated cell migration. Adapted from [13].
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Interestingly, genes encoding Rho-GTPases themselves are only rarely mutated in human cancers [21, 22],
despite their markedly elevated expression and activity [23]. This observation lends further support to the
indirect, upstream role of TP53 in regulating activity of these key migratory proteins. Downstream of
Rho-GTPases, altered expression of numerous effector proteins including ROCK2, LIMK1 and myosin
light-chain (MLC) kinase through altered transcriptional regulation or mutation have been implicated in a
variety of metastatic cancers, including both ADC and SqCC NSCLCs [24–26] (figure 3). These findings
suggest an important role of downstream Rho-GTPase pathway components in regulating tumour cell
migration and subsequent disease progression.
Therapeutic targeting of cancer cell migration
The development of novel therapies to prevent NSCLC progression represents an unmet need in cancer
therapy. Reducing preinvasive cancer cell migration speaks to this ideal and the development of
pharmacotherapies to reduce tumour cell migration has the potential to improve overall disease mortality.
Targeting Rho-GTPase-dependent signalling is attractive as a potential cancer therapy given that the
effects of TP53 mutation on cancer cell migration are reversible following RhoA and ROCK inhibition
[27]. Towards this end, the small molecule ROCK inhibitor Y27632 has been shown to inhibit migration
and invasion in a variety of cancer cell types in vitro, including pancreatic adenocarcinoma [18],
melanoma [19] and invasive oesophageal carcinoma [28]. Similarly, ROCK inhibition with the small
molecule H-1152 reduced in vitro migration of the murine melanoma cell line B16F10 and limited the
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FIGURE 2 Cell migration is mediated by Rho-GTPase protein activity. Cell polarity is mediated by Cdc42
activity. Membrane protrusions are formed and are dependent on Rac1 (lamellipodia) and Cdc42 (filopodia)
activity. Membrane protrusions grip the extracellular matrix via RhoA-dependent focal adhesion (FA)
formation and actomyosin contraction pulls the cell forward via RhoA effector protein Rho-associated kinase
(ROCK)-mediated phosphorylation of myosin light chain kinase. Disassembly of focal adhesion and tail
retraction is also mediated by RhoA activity. ECM: extracellular matrix.
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FIGURE 3 Rho-GTPases and downstream effector proteins involved in cell motility. RhoA acts via the effector
proteins ROCK (RhoA effector protein Rho-associated kinase) and mDia to mediate actomyosin contraction
and actin stabilisation. Rac1 acts via WAVE and PI-4-PK5 to mediate actin polymerisation and is involved in
membrane protrusions. Cdc42 acts via PAR6 to mediate cell polarity and N-WASP to mediate actin
polymerisation.
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cells’ ability to form pulmonary metastases in vivo [29]. Clinically, the potent ROCK inhibitor and
vasodilator fasudil is in commercial use in Japan, where it has been shown to be a safe and well-tolerated
drug used to prevent cerebral vasospasm post-subarachnoid haemorrhage [30]. Similarly, the direct RhoA
inhibitor BA-210, used to treat spinal cord injuries, also has a good safety profile in humans [31].
However, the effect of these drugs on cell migration is as yet unknown.
Upstream of Rho-GTPase signalling, PI3K inhibitors have been explored as potential cancer therapies [32],
and several of these are either in use or currently undergoing clinical trials in a variety of human cancers [33].
Notably, the PI3K inhibitor idelalisib is currently approved to treat relapsed chronic lymphocytic leukaemia
(CLL), and has recently been approved by the European Medicines Agency for the first-line treatment of CLL
patients with TP53 mutations who are not fit for first-line chemotherapy [34]. Targeting PI3K signalling is
also of growing interest in the treatment of NSCLC [35], although the effect of PI3K inhibition on lung cancer
cell migration remains unknown. Rapamycin, an immunosuppressant and well-known inhibitor of PI3K/
mTOR activity, has also demonstrated promising anticancer effects in solid tumours [36, 37]. Interestingly,
rapamycin has been shown to inhibit cancer cell migration in vitro via suppression of mTOR-mediated
lamellipodia formation, actin reorganisation and focal adhesion formation [38]. These effects were
Rho-GTPase dependent, with reduced RhoA, Rac1 and Cdc42 expression in rapamycin-treated cells [39].
In addition to upstream activators and downstream effectors, localisation of Rho-GTPase proteins at the
plasma membrane is critical for effective signalling, and is achieved by a series of post-translational
modifications including C-terminal cysteine prenylation [40]. Rho-GTPase prenylation is dependent on
geranylgeranyltransferase-I, and efficient enzyme activity is dependent on a steady supply of geranylgeranyl
pyrophosphate (GGPP) within the cell, the synthesis of which is rate-limited by HMGCoA-reductase.
Indeed, HMGCoA-reductase inhibitors (statins) have been shown to reduce Rac1 association with cell
membranes and subsequently reduce Rac1 cellular effects, including cell morphology and phagocytosis [41].
Simvastatin has been shown to inhibit migration of human and murine microglial cells at baseline and in
response to chemokine stimulation, with associated distorted actin distribution [42]. This effect is reversed
by co-incubation with L-mevalonate, indicating an inhibitory dependence on disruption of the mevalonate
pathway and HMG-CoA reductase activity [42]. Similarly, treatment of human cultured prostate cancer
cells with simvastatin or rosuvastatin reduced colony-forming ability and migration towards the powerful
chemoattractant bone marrow stroma, with normal migratory behaviour restored with the addition of
mevalonate or GGPP [43]. In addition, epidemiological data demonstrate lower rates of prostate cancer
progression in patients taking statins [44–46].
Despite these positive findings, Rho-GTPase inhibition is not without challenges and the use of
Rho-GTPase inhibitors for human lung cancers remains unexplored. Rho-GTPase is heavily involved in
organ development and repair, making delivery of broad-acting inhibitors potentially precarious. In utero,
murine germline ROCK1 deletion causes defective eyelid closure, omphalocoele (nonclosure of the ventral
body wall) and widespread epithelial dysfunction [47]. Similarly, 90% of ROCK II knockouts die in utero
due to placental dysfunction and intrauterine growth retardation [48]. In normal human lung epithelial
cells, Rho-GTPase activity is essential for normal wound repair [49, 50]. However, in bovine epithelial cells,
RhoA inhibition via PKC activation was associated with improved wound closure [51]. Thus, the precise
interplay of Rho-GTPase activity regulating normal and cancerous lung epithelial cell migration remains
unclear. It may therefore be a more sensible approach when designing potential cancer therapeutics to
target downstream effector proteins such as ROCK and mDia, rather than Rho-GTPase proteins themselves.
Future directions
Given the disparity in mechanisms underlying cell migration across tissue types, it remains of critical
importance to characterise the role of various Rho-GTPase pathway components in normal and cancerous
lung epithelial cell migration. Towards this end, methods have recently been developed to isolate and
expand primary human bronchial epithelial cells that maintain a normal karyotype and multipotent
differentiation capacity [52]. In addition, murine models of both human adeno and squamous NSCLCs,
generated via targeted transgenesis or cutaneous application of chemical carcinogens, are available [53–56].
Taken together, these in vitro and in vivo models offer unique opportunities for monitoring the effects of
Rho-GTPase activity on lung epithelial cell migration. In addition, human bronchoscopic surveillance
using AFB will allow accurate assessment of the migration of clonally distinct preinvasive SqCC lesions.
Although the numbers of patients undergoing routine surveillance bronchoscopy remain small, these
studies should nonetheless improve our understanding of the earliest stages of disease pathogenesis.
Interestingly, the widespread use of statins within these patients may also permit retrospective analysis of
the effects of statin-dependent Rho-GTPase inhibition on preinvasive disease progression.
Clinically, targeting the Rho-GTPase signalling pathway to reduce early NSCLC disease progression appears
to hold promise. Future in vitro and in vivo studies involving small molecule Rho-GTPase inhibitors will
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allow precise characterisation of the molecular pathways involved in preinvasive lung cancer cell migration,
and propel the use of targets of cell migration towards clinical benefit. Furthermore, the wealth of therapies
already available and licenced for human use provides great opportunity for rapid translation of preclinical
data into effective therapies for lung cancer patients.
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